5月9日，国泰海通证券发表研究报告称，2024年及2025年第一季度医药各细分板块业绩表现分化，创新药带动制药板块景气度持续向上，多个细分板块有望迎来拐点，持续推荐创新药等主线。2024年及2025年第一季度医药各细分板块业绩表现分化。2024年医药板块整体收入同比下滑1.5%，归母净利润同比下滑12.5%；从具体板块来看，医疗耗材、化学制剂、血液制品表现较好，其中医疗耗材收入、归母净利润分别同比...
Source Link5月9日，国泰海通证券发表研究报告称，2024年及2025年第一季度医药各细分板块业绩表现分化，创新药带动制药板块景气度持续向上，多个细分板块有望迎来拐点，持续推荐创新药等主线。2024年及2025年第一季度医药各细分板块业绩表现分化。2024年医药板块整体收入同比下滑1.5%，归母净利润同比下滑12.5%；从具体板块来看，医疗耗材、化学制剂、血液制品表现较好，其中医疗耗材收入、归母净利润分别同比...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.